Optimized AAV capsids for basal ganglia diseases show robust potency and distribution
Abstract Huntington’s disease and other disorders of the basal ganglia create challenges for biomolecule-based medicines given the poor accessibility of these deep brain structures following intracerebral or intravascular delivery. Here, we found that low dose, low volume delivery of unbiased AAV li...
Saved in:
| Main Authors: | D. E. Leib, Y. H. Chen, L. Tecedor, P. T. Ranum, M. S. Keiser, B. C. Lewandowski, E. M. Carrell, S. Arora, I. Huerta-Ocampo, D. Lai, C. M. Fluta, C. Cheng, X. Liu, B. L. Davidson |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-60000-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Anatomy of the Basal Ganglia
by: Kate E. Watkins, et al.
Published: (2019-08-01) -
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
by: Marina Pavlou, et al.
Published: (2021-02-01) -
The Basal Ganglia and Motor Control
by: Henk J. Groenewegen
Published: (2003-01-01) -
Advancing AAV technology: From capsid design to scalable manufacturing
by: Daniel Stone, et al.
Published: (2025-06-01) -
Learning Reward Uncertainty in the Basal Ganglia.
by: John G Mikhael, et al.
Published: (2016-09-01)